Sorafenib downregulates Mcl-1 protein levels in a time- and dose-dependent manner to induce apoptosis in renal, colon and breast tumour lines (Rahmani et al, 2005; Yu et al, 2005). The gene discussed is MCL1; the disease is breast neoplasm.